US Smart Pills Market to Reach US$ 619.10 Million by 2033 | CAGR 12.9% | Gastrointestinal Diagnostics & AI-Enabled Devices Drive Growth | Key Players: Medtronic, CapsoVision, Olympus, IntroMedic

US Smart Pills Market Size and Growth

The US Smart Pills Market reached US$ 235.07 million in 2024 and is projected to grow to US$ 619.10 million by 2033, expanding at a CAGR of 12.9% during the forecast period of 2025-2033. Smart pills are innovative ingestible devices that integrate sensors with medication, enabling real-time health monitoring, minimally invasive diagnostics, and improved disease management. The market growth is driven by the rising prevalence of gastrointestinal disorders, including irritable bowel syndrome (IBS) and Crohn's disease, coupled with the increasing demand for precise, patient-friendly diagnostic solutions. In the U.S., the FDA's approval of advanced devices such as the CapsoCam Plus and PillCam Genius has accelerated adoption. Key trends shaping the market include the development of AI-enabled smart pills for real-time data analysis, wireless systems for continuous patient monitoring, and pills that combine targeted drug delivery with diagnostics, reinforcing their role in personalized medicine and chronic disease management.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):-https://www.datamintelligence.com/download-sample/u-s-smart-pills-market?Juli

Recent Developments:

✅ November 2025: CapsoVision launched an upgraded version of the CapsoCam Plus smart pill with enhanced 360-degree imaging and AI-driven analytics for improved gastrointestinal diagnostics.

✅ October 2025: Medtronic introduced the PillCam Genius with real-time wireless data transmission and cloud-based analysis, allowing clinicians to monitor patients remotely and reduce diagnostic delays.

✅ September 2025: Proteus Digital Health partnered with a leading pharmaceutical company to develop ingestible sensors that combine drug delivery with real-time monitoring of medication adherence and gastrointestinal health.

✅ July 2025: FDA approved a next-generation AI-enabled smart pill capable of targeted drug delivery and continuous monitoring of gut motility, improving treatment outcomes for chronic gastrointestinal disorders.

✅ May 2025: Venture capital firms invested $45 million in emerging smart pill startups focused on ingestible devices that integrate diagnostics, therapeutic monitoring, and AI-powered predictive analytics for personalized medicine.

Mergers & Acquisitions:

✅ 2025: Medtronic acquired Proteus Digital Health's ingestible sensor division to expand its smart pill portfolio and integrate AI-driven analytics with existing gastrointestinal diagnostic solutions.

✅ 2024: CapsoVision merged with EndoTech Solutions to develop next-generation 360-degree imaging smart pills with enhanced data transmission capabilities.

✅ 2024: Omron Healthcare acquired a minority stake in PillCam Genius to jointly develop AI-enabled smart pills for real-time monitoring of gastrointestinal motility and patient adherence.

✅ 2023: Proteus Digital Health partnered with a leading U.S. pharmaceutical company through an acquisition deal focused on integrating ingestible sensors with oral medications for personalized treatment.

✅ 2023: SmartPill Technologies, a startup specializing in wireless smart pills, was acquired by a larger medtech company to accelerate commercialization and expand its presence in the U.S. gastrointestinal diagnostics market.

Buy Now & Unlock 360° Market Intelligence:-https://www.datamintelligence.com/buy-now-page?report=u-s-smart-pills-market?Juli

Key Players:

• Medtronic - Holds a 22.5% share, driven by its portfolio of AI-enabled ingestible sensors and smart pill diagnostics for gastrointestinal disorders.

• CapsoVision, Inc. - Holds a 16.3% share, supported by its 360-degree imaging smart capsule technologies and advanced data transmission solutions.

• Olympus - Holds a 13.7% share, fueled by its endoscopy devices and integration of smart pill imaging for minimally invasive diagnostics.

• Check-Cap - Holds a 10.2% share, driven by its non-invasive smart capsule solutions for colorectal cancer screening.

• IntroMedic - Holds a 9.1% share, supported by PillCam capsule endoscopy and AI-enhanced diagnostics for gastrointestinal monitoring.

• JINSHAN Science & Technology (Group) Co., Ltd. - Holds a 7.8% share, focused on smart pill manufacturing and AI-assisted drug delivery systems.

• EtectRx - Holds a 6.5% share, fueled by ingestible sensors for real-time adherence monitoring and telehealth integration.

• Shenzhen Jifu Medical Technology Co., Ltd. - Holds a 5.4% share, driven by smart pill innovations for gastrointestinal imaging and patient monitoring.

• MEDISPACE - Holds a 5.0% share, supported by the development of capsule endoscopy and integrated digital health solutions.

• RF Co., Ltd. - Holds a 3.5% share, focusing on R&D for ingestible electronics and AI-based smart pill diagnostics.

Market Segmentation:

➥By Product Type: The market is segmented into Capsule Endoscopy, Drug Delivery, and Patient Monitoring. Capsule Endoscopy dominates due to its non-invasive diagnostic capabilities and high adoption in gastrointestinal disease monitoring. Drug Delivery capsules are gaining traction as they enable targeted treatment with real-time monitoring, while Patient Monitoring solutions are increasingly integrated with AI and wireless platforms for continuous health data collection.

➥By Target Area: The market is categorized based on the anatomical focus of smart pills, including the Esophagus, Stomach, Small Intestine, and Large Intestine. Among these, the Small Intestine segment holds the largest share, owing to the prevalence of small bowel disorders and the challenges of conventional endoscopy access. Smart pills designed for the Stomach and Esophagus are also growing due to increasing gastrointestinal screenings, while Large Intestine capsules are expanding for colon disease monitoring.

➥By Disease Indication: The market is divided into Barrett's Esophagus Disease, Small Bowel Disease, Colon Disease, and Others. Small Bowel Disease represents the largest segment due to the high incidence of Crohn's disease, bleeding disorders, and other small intestine conditions. Colon Disease capsules are widely adopted for colorectal cancer screening, whereas Barrett's Esophagus Disease capsules are used for early detection in at-risk populations.

➥By End User: The market is segmented into Hospitals & Clinics, Diagnostic Centers, and Others. Hospitals & Clinics lead the adoption due to established infrastructure, skilled personnel, and integration with electronic health records. Diagnostic Centers are increasingly deploying smart pill solutions for outpatient gastrointestinal screenings, and Others include research institutions and specialized healthcare facilities using these devices for clinical trials and advanced diagnostics.

Regional Insights:

North America - 65% (USD 152.8 Million in 2024): North America dominates the smart pills market, with the U.S. leading due to high adoption of advanced diagnostic technologies, rising prevalence of gastrointestinal disorders, and strong healthcare infrastructure. FDA approvals of innovative devices like CapsoCam Plus and PillCam Genius have accelerated market growth.

Europe - 18% (USD 42.3 Million in 2024): Europe holds a significant share due to growing healthcare investments, awareness of minimally invasive diagnostics, and early adoption of capsule endoscopy in countries such as Germany, France, and the UK. Increasing research initiatives and collaborations among hospitals and tech companies are fueling market expansion.

Asia-Pacific - 12% (USD 28.2 Million in 2024): The Asia-Pacific market is growing rapidly, driven by rising gastrointestinal disease prevalence, increasing healthcare expenditure, and government initiatives to promote smart diagnostics in countries like Japan, China, and India. Market growth is also supported by the introduction of cost-effective smart pill solutions.

Speak to Our Analyst and Get Customization in the report as per your requirements:-https://www.datamintelligence.com/customize/u-s-smart-pills-market?Juli

Market Dynamics:

Drivers:
Rising Demand for Minimally Invasive Devices
The U.S. smart pills market is being driven by the growing preference for minimally invasive procedures, which offer multiple advantages over traditional invasive methods, including reduced discomfort, shorter recovery times, and lower risk of complications. For instance, conventional endoscopic procedures often require sedation and can be uncomfortable, whereas smart pills can be easily ingested without anesthesia, providing a non-invasive alternative for patients.

Smart pills enhance diagnostic accuracy by capturing real-time data and high-resolution images from within the gastrointestinal (GI) tract. Unlike traditional methods that rely on indirect measurements or external imaging techniques, these devices allow healthcare professionals to obtain a detailed and comprehensive view of internal health, enabling more informed clinical decisions.

Technological Advancements:
Continuous research and development in smart pill technology, including AI integration, wireless transmission systems, and improved imaging capabilities, is further driving adoption. These advancements enable targeted diagnostics, real-time data analysis, and improved patient monitoring, all contributing to the expansion of the U.S. smart pills market.

Restraints:
Privacy and Data Security Concerns
Despite their benefits, smart pills raise significant concerns about privacy and data security. These devices collect sensitive health information, including physiological parameters, medication adherence data, and potentially real-time internal imaging.

Ensuring secure data transmission, storage, and handling is crucial to maintain trust among patients and healthcare providers. Unauthorized access or misuse of such sensitive data could lead to privacy violations, regulatory challenges, and slowed adoption, limiting market growth.

📌 Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription

☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape

✅ Sustainability Impact Analysis

✅ KOL / Stakeholder Insights

✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots

✅ Market Volatility & Emerging Risks Analysis

✅ Quarterly Industry Report Updated

✅ Live Market & Pricing Trends

✅ Import-Export Data Monitoring

☛ Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?Juli

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.